Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,796 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07365995RecruitingPhase 3
New drug for advanced prostate cancer vs. standard chemo
This trial tests a new drug called BNT324 against the standard chemotherapy docetaxel for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the new treatment can help control the cancer better.
Santa Barbara, CaliforniaAges 18 years+ - NCT06820463RecruitingPhase 2
Study of telisotuzumab adizutecan plus chemo for metastatic colorectal cancer
This trial tests a new drug combination for people with metastatic colorectal cancer. The study includes an experimental antibody-drug conjugate (telisotuzumab adizutecan) plus standard chemotherapy and targeted therapies, to see if it works better than current options.
Duarte, CaliforniaAges 18 years+ - NCT07659782RecruitingPhase 2
Study of VS-7375 for KRAS G12D lung cancer
This trial tests a new drug, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. It's for those who have already tried chemo and immunotherapy, and whose cancer has continued to grow.
Scottsdale, ArizonaAges 18 years+ - NCT07721181Recruiting
STEP-UP: Higher radiation for recurrent rectal cancer
This trial tests giving a higher dose of radiation to people whose rectal cancer has come back in the pelvis after surgery and cannot be removed. It aims to see if more radiation can help control the tumor when surgery is not an option.
Maastricht, LimburgAges 18 years+ - NCT04989985RecruitingPhase 2
SOX chemotherapy plus immunotherapy for junction stomach-esophagus cancer
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
Guangzhou, GuangdongAges 18–75 - NCT05033691Recruiting
Osimertinib plus early brain radiation versus osimertinib alone
This trial tests whether starting focused radiation to brain spots early (called SRS) along with osimertinib works better than taking osimertinib alone. It is for people with lung cancer that has an EGFR mutation and has not yet caused major brain symptoms.
JerusalemAges 18–120 - NCT04991948RecruitingPhase 1
Testing pembrolizumab after CYAD-101 plus FOLFOX in colon cancer
This early-phase study tests whether adding pembrolizumab after CYAD-101 and FOLFOX chemotherapy can help treat metastatic colon or rectal cancer. It is mainly looking for safety and signs of how well the treatment works in people whose cancer has not responded to prior therapy.
Jacksonville, FloridaAges 18 years+ - NCT05334459Recruiting
Radiation and medicines after surgery for new metastatic breast cancer
This trial looks at giving radiation and anti-cancer medicines after surgery to treat newly diagnosed (de novo) metastatic breast cancer. It may help patients by improving local control of the breast area while also treating cancer throughout the body.
AnkaraAges 18–80 - NCT04951635RecruitingPhase 3
Almonertinib after chemoradiation for stage III lung cancer
This Phase 3 trial tests whether almonertinib given after standard chemoradiation can help people with stage III, non-surgical lung cancer live longer and/or control the cancer. It is for tumors with specific EGFR mutations linked to sensitivity to EGFR-targeted medicines.
Ji'nan, ShandongAges 18 years+ - NCT05397769RecruitingPhase 2
Test envafolimab with chemoradiation for advanced nasopharyngeal cancer
This trial studies whether adding envafolimab (an immune medicine) to standard chemo and radiation works better for people with locally advanced, untreated nasopharyngeal cancer. It may help the immune system attack the cancer while treatment shrinks it.
Guangzhou, GuangdongAges 18–65 - NCT04263298RecruitingPhase 3
Fulvestrant or capecitabine after chemo for metastatic breast cancer
This Phase 3 trial compares two medicines—fulvestrant versus capecitabine—as “maintenance” treatment after your first chemo helps control metastatic breast cancer. It aims to see which one helps people live longer with better disease control.
Guangzhou, GuangdongAges 18–75 - NCT04014530RecruitingPhase 1/Phase 2
Testing pembrolizumab plus ataluren for metastatic dMMR or pMMR cancer
This early-phase trial tests pembrolizumab combined with ataluren for people with metastatic colorectal cancer that has either dMMR or pMMR, and for metastatic dMMR endometrial cancer. The goal is to see whether this combination can shrink tumors or improve outcomes for cancers with specific mismatch repair (MMR) features.
Amsterdam, North HollandAges 18 years+ - NCT05725200RecruitingPhase 2
Personalized treatment plan for metastatic colon or rectal cancer
This Phase 2 trial tests an individualized treatment chosen from your tumor’s lab testing (genetic and RNA profile plus a drug-sensitivity test from your tumor cells). It may help by matching you to targeted anti-cancer drugs that are most likely to work for your specific cancer.
OsloAges 18 years+ - NCT05753657RecruitingEarly Phase 1
Testing insulin and blood sugar monitoring with pioglitazone
This early study tests whether adding pioglitazone, along with close blood-sugar (glucose/insulin) monitoring, can help control high insulin and high blood sugar in people starting alpelisib for metastatic breast cancer. It may help reduce blood-sugar side effects from alpelisib.
HaifaAges 18–85 - NCT02448992RecruitingPhase 2/Phase 3
Brain radiation that avoids the memory area in lung cancer
This trial studies a “prophylactic” (preventive) type of brain radiation for people with lung cancer that has spread to nearby lymph nodes but not to the brain. It aims to lower the chance of brain metastases while protecting the hippocampus, an area linked to memory.
TaoyuanAges 18–80 - NCT04539977RecruitingPhase 2
PD-L1 antibody plus chemotherapy for limited-stage small-cell lung cancer
This Phase 2 study tests whether adding a PD-L1 antibody to chemotherapy helps people with newly diagnosed limited-stage small-cell lung cancer live longer and control the cancer better. It may benefit patients who have not had any prior cancer treatment for SCLC and can meet health and lab requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05857800Recruiting
Studying how lung tumor treatment affects the tumor environment
This trial studies how “before-surgery” (neoadjuvant) lung cancer treatments change the tumor environment by monitoring patients during care. It may help doctors better choose therapies and predict who benefits from treatment.
ShanghaiAges 18 years+ - NCT05904964RecruitingPhase 3
Targeted drug for hormone-positive, HER2-low metastatic breast cancer
This Phase 3 trial tests disitamab vedotin (a targeted drug) in people with hormone receptor–positive, HER2-low metastatic breast cancer that can’t be cured with surgery or radiation. It aims to see whether the drug can control the cancer better than current standard care.
Guangzhou, GuangdongAges 18–70 - NCT04728724RecruitingPhase 2
Check immune treatment before surgery for stage III lung cancer
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
ShanghaiAges 18–75 - NCT05962502RecruitingPhase 2
Cetuximab plus irinotecan for left-sided RAS/BRAF wild-type colon cancer
This Phase 2 trial tests whether adding cetuximab to irinotecan can control metastatic colorectal cancer that has returned or worsened after standard treatments. It targets people whose tumor is left-sided and shows “wild-type” RAS and BRAF genes on blood testing after prior therapy.
Guangzhou, GuangdongAges 18 years+ - NCT06041776RecruitingPhase 3
Befotertinib after surgery for early-stage lung cancer with EGFR mutation
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
BeijingAges 18 years+ - NCT05916261RecruitingEarly Phase 1
Personalized pancreatic cancer vaccines with pembrolizumab
This early-phase trial tests a personalized cancer vaccine made from your tumor, along with pembrolizumab, to help the immune system attack advanced pancreatic cancer. It may be an option if your cancer has specific immune “targets” and if you meet several health, lab, and infection requirements.
Qionghai, HainanAges 18 years+ - NCT06118762RecruitingPhase 4
Study of fruquintinib plus raltitrexed for advanced colorectal cancer
This trial tests two drugs, fruquintinib and raltitrexed, for people with metastatic colorectal cancer that has stopped responding to or is no longer tolerable after standard treatments like fluorouracil, oxaliplatin, and irinotecan. The goal is to see if this combination can help shrink or control the cancer.
Nanchang, JiangxiAges 18 years+ - NCT04992780RecruitingPhase 2
Hypo-fractionated radiation versus standard radiation for lung cancer
This study compares two different radiation schedules for stage III non-small cell lung cancer, both combined with chemotherapy and immunotherapy. It aims to see whether giving radiation in a different way can work as well (or better) and be safe while treating the cancer.
Kansas City, KansasAges 18 years+
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,796 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.